J05 Interim results from cohort 1 of the double-blind, dose-escalation phase I/II clinical trial of amt-130 (HD-genetrx-1) for early-stage huntington’s disease (HD)

Erin Furr Stimming; Victor Sung; Claudia Testa; Sandra Kostyk; Christopher A Ross; Ali Samii; Michael D Geschwind; Deborah Hall; Praveen Dayalu; Russell Lonser; Brad Elder; Paul S Larson; David L Cooper; Marcie Clarkin; Talaha M Ali; Ricardo E Dolmetsch; on behalf of the AMT-130-01 Investigators

doi:10.1136/jnnp-2022-ehdn.255

Article info

J: Clinical therapeutics

J05 Interim results from cohort 1 of the double-blind, dose-escalation phase I/II clinical trial of amt-130 (HD-genetrx-1) for early-stage huntington’s disease (HD)

Authors

Erin Furr Stimming McGovern Medical School, Houston, Texas, USA PubMed articles Google scholar articles
Victor Sung University of Alabama School of Medicine, Birmingham, Alabama, USA PubMed articles Google scholar articles
Claudia Testa University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA PubMed articles Google scholar articles
Sandra Kostyk Ohio State University Wexner Medical Center, Columbus, Ohio, USA PubMed articles Google scholar articles
Christopher A Ross Johns Hopkins University School of Medicine, Baltimore, Maryland, USA PubMed articles Google scholar articles
Ali Samii University of Washington Medical Center, Seattle, Washington, USA PubMed articles Google scholar articles
Michael D Geschwind University of California, San Francisco, California, USA PubMed articles Google scholar articles
Deborah Hall Rush University Medical Center, Chicago, Illinois, USA PubMed articles Google scholar articles
Praveen Dayalu University of Michigan Medical School, Ann Arbor, Michigan, USA PubMed articles Google scholar articles
Russell Lonser The Ohio State University College of Medicine, Columbus, Ohio, USA PubMed articles Google scholar articles
Brad Elder The Ohio State University College of Medicine, Columbus, Ohio, USA PubMed articles Google scholar articles
Paul S Larson University of Arizona Banner UMC-Tucson, Southern Arizona VA Health Care System, Tucson, Arizona, US PubMed articles Google scholar articles
David L Cooper uniQure Inc., Lexington, MA, USA PubMed articles Google scholar articles
Marcie Clarkin uniQure Inc., Lexington, MA, USA PubMed articles Google scholar articles
Talaha M Ali uniQure Inc., Lexington, MA, USA PubMed articles Google scholar articles
Ricardo E Dolmetsch uniQure Inc., Lexington, MA, USA PubMed articles Google scholar articles
on behalf of the AMT-130-01 Investigators
Google scholar articles

Citation

Furr Stimming E, Sung V, Testa C, et al

J05 Interim results from cohort 1 of the double-blind, dose-escalation phase I/II clinical trial of amt-130 (HD-genetrx-1) for early-stage huntington’s disease (HD)

Journal of Neurology, Neurosurgery & Psychiatry 2022;93:A95.

Publication history

First published September 12, 2022.

Online issue publication

September 29, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password